An opinion piece highlights the growing concerns among medical professionals about the exacerbating effects the COVID-19 pandemic may have among people with opioid use disorder.
Patients on hemodialysis who use opioids concurrently with a short-acting benzodiazepine are especially at risk for early death, a study found.
In the cohort without baseline MDD, baseline nonmedical opioid use was significantly associated with an increased risk of incident depressive symptoms, but not MDD, over 3 years.
In 2018, opioid overdose deaths declined, but deaths involving alcohol, suicide, synthetic opioids, and other psychostimulants rose.
Excess mortality occurred as the result of a number of causes, including overdose, injuries, and both infectious and noncommunicable diseases.
Alkermes has decided to expand the number of retail pharmacies and clinics where patients can receive access to Aristada (aripiprazole lauroxil) and Vivitrol (naltrexone extended-release injectable suspension).
Financial incentives improved X-waiver training completion and buprenorphine prescribing rates in emergency department physicians.
The estimated rate of past-year methamphetamine use was 6.6 per 1,000 adults during 2015 to 2018.
People who receive additional treatment following medically managed opioid withdrawal have reduced mortality compared with those who do not receive treatment.
Up to 75,000 more people could die from drug or alcohol misuse and suicide during the COVID-19 pandemic.
